|
1.
|
|
12 p, 1.2 MB |
Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease
/
Startin, Carla M. (LonDownS Consortium (London Down Syndrome Consortium)) ;
Ashton, Nicholas J. (University of Gothenburg) ;
Hamburg, Sarah (LonDownS Consortium (London Down Syndrome Consortium)) ;
Hithersay, Rosalyn (LonDownS Consortium (London Down Syndrome Consortium)) ;
Wiseman, Frances K. (University College London) ;
Mok, Kin Y. (Hong Kong University of Science and Technology) ;
Hardy, John (University College London) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Lovestone, Simon (University of Oxford) ;
Parnetti, Lucilla (University of Perugia) ;
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit)) ;
Hye, Abdul (Maudsley NHS Foundation) ;
Fisher, Elisabeth ;
Nizetic, Dean ;
Tybulewicz, Victor ;
Karmiloff-Smith, Anette ;
Al-Janabi, Tamara ;
Zhang, David ;
Strydom, André (LonDownS Consortium (London Down Syndrome Consortium)) ;
Universitat Autònoma de Barcelona
Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and controls will aid in understanding AD development in DS. [...]
2019 -  10.1186/s13195-019-0477-0
Alzheimer's research & therapy, Vol. 11 Núm. 1 (21 2019) , p. 26
|
|
|
2.
|
|
9 p, 1012.4 KB |
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity : A cross-sectional analysis from the AB255 Study
/
Pérez-Grijalba, Virginia (Araclon Biotech S.L.) ;
Arbizu, Javier (Clínica Universidad de Navarra) ;
Romero, Judith (Araclon Biotech S.L.) ;
Prieto, Elena (Clínica Universidad de Navarra) ;
Pesini, Pedro (Araclon Biotech S.L.) ;
Sarasa, Leticia (Araclon Biotech S.L.) ;
Guillen, Fernando (Clínica Universidad de Navarra) ;
Monleón, Inmaculada (Araclon Biotech S.L.) ;
San-José, Itziar (Araclon Biotech S.L.) ;
Martínez-Lage, Pablo (Fundación CITA-Alzheimer) ;
Munuera, Josep (Institut de Recerca Sant Joan de Déu) ;
Hernández, Isabel (Instituto de Salud Carlos III) ;
Buendía, Mar (Universitat Internacional de Catalunya) ;
Sotolongo-Grau, Oscar (Universitat Internacional de Catalunya) ;
Alegret, Montserrat (Instituto de Salud Carlos III) ;
Ruiz, Agustín (Instituto de Salud Carlos III) ;
Tárraga, Lluís (Instituto de Salud Carlos III) ;
Boada, Mercè (Instituto de Salud Carlos III) ;
Sarasa, Manuel (Araclon Biotech S.L.) ;
Goñi Imízcoz, Miguel (Hospital Divino Vallés (Burgos)) ;
Pujadas, Francesc ;
Villarejo, Alberto ;
Frank, Ana ;
Peña-Casanova, Jordi ;
Fernández, Manuel ;
Piñol, Gerard ;
Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ;
Gil, Pedro ;
Pascual, Luis F. ;
Aguilar Barberà, Miquel ;
Frisoni, Giovanni B. ;
Matias-Guiu, Jorge ;
Andreasen, Niels ;
Antúnez, Carmen ;
Universitat Autònoma de Barcelona
To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer's disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ) levels with the presence of pathological accumulation of Aβ in the brain measured by amyloid-PET. [...]
2019 - 10.1186/s13195-019-0549-1
Alzheimer's research & therapy, Vol. 11 Núm. 1 (january 2019) , p. 96
|
|
|
3.
|
|
4 p, 880.7 KB |
β-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer's disease
/
Mohaupt, Pablo (Université de Montpellier) ;
Pons, Marie-Laure (Université de Montpellier) ;
Vialaret, Jérôme (Université de Montpellier) ;
Delaby, Constance (Institut d'Investigació Biomèdica Sant Pau) ;
Hirtz, Christophe (Université de Montpellier) ;
Lehmann, Sylvain (Université de Montpellier) ;
Universitat Autònoma de Barcelona
Synaptic degeneration is an early event closely associated with the course of Alzheimer's disease (AD). The identification of synaptic blood biomarkers is, therefore, of great interest and clinical relevance. [...]
2022 - 10.1186/s13195-022-01125-1
Alzheimer's research & therapy, Vol. 14 (november 2022)
|
|
|
4.
|
|
19 p, 3.1 MB |
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients
/
Lennol, Matthew Paul (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Sánchez-Domínguez, Irene (Universitat de Barcelona. Institut de Neurociències) ;
Cuchillo-Ibañez, Inmaculada (Instituto de Investigación Sanitaria y Biomédica de Alicante) ;
Camporesi, Elena (Institute of Neuroscience and Physiology. Department of Psychiatry and Neurochemistry. the Sahlgrenska Academy at the University of Gothenburg) ;
Brinkmalm, Gunnar (Institute of Neuroscience and Physiology. Department of Psychiatry and Neurochemistry. the Sahlgrenska Academy at the University of Gothenburg) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Soria, Guadalupe (Universitat de Barcelona. Laboratori de Neuroanatomia Quirúrgica. Facultat de Medicina i Ciències de la Salut) ;
Aguado, Fernando (Universitat de Barcelona. Institut de Neurociències) ;
Zetterberg, Henrik (Hong Kong Center for Neurodegenerative Diseases) ;
Blennow, Kaj (Clinical Neurochemistry Laboratory. Sahlgrenska University Hospital) ;
Sáez-Valero, Javier (Instituto de Investigación Sanitaria y Biomédica de Alicante) ;
Universitat Autònoma de Barcelona
Objective: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer's disease (AD) patients. Methods: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. [...]
2022 - 10.1186/s13195-022-01108-2
Alzheimer's research & therapy, Vol. 14 Núm. 1 (december 2022) , p. 161
|
|
|
5.
|
|
19 p, 1.3 MB |
State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease
/
Hampel, Harald (Eisai Inc. Neurology Business Group) ;
Shaw, Leslie M. (Perelman School of Medicine. Department of Pathology and Laboratory Medicine. University of Pennsylvania) ;
Aisen, Paul (USC Alzheimer's Therapeutic Research Institute) ;
Chen, Christopher (Memory Aging and Cognition Centre. Departments of Pharmacology and Psychological Medicine. Yong Loo Lin School of Medicine. National University of Singapore) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Iwatsubo, Takeshi (Department of Neuropathology. Graduate School of Medicine. The University of Tokyo) ;
Iwata, Atsushi (Tokyo Metropolitan Geriatric Hospital) ;
Yamada, Masahito (Department of Neurology and Neurobiology of Aging. Kanazawa University Graduate School of Medical Science) ;
Ikeuchi, Takeshi (Department of Molecular Genetics. Brain Research Institute. Niigata University) ;
Jia, Jianping (Innovation Center for Neurological Disorders. Department of Neurology. Xuan Wu Hospital. Capital Medical University) ;
Wang, Huali (Dementia Care and Research Center. Peking University Institute of Mental Health (Sixth Hospital). Beijing Dementia Key Lab. National Clinical Research Center for Mental Disorders) ;
Teunissen, Charlotte E. (Amsterdam University Medical Centers (AUMC)) ;
Peskind, Elaine (VA Northwest Mental Illness Research. Education and Clinical Center. VA Puget Sound Health Care System. Department of Psychiatry and Behavioral Sciences. University of Washington School of Medicine) ;
Blennow, Kaj (Clinical Neurochemistry Laboratory. Sahlgrenska University Hospital) ;
Cummings, Jeffrey (Chambers-Grundy Center for Transformative Neuroscience. Department of Brain Health. School of Integrated Health Sciences. University of Nevada Las Vegas (UNLV)) ;
Vergallo, Andrea (Eisai Inc. Neurology Business Group) ;
Universitat Autònoma de Barcelona
Recent advances in developing disease-modifying therapies (DMT) for Alzheimer's disease (AD), and the recognition that AD pathophysiology emerges decades before clinical symptoms, necessitate a paradigm shift of health-care systems toward biomarker-guided early detection, diagnosis, and therapeutic decision-making. [...]
2022 - 10.1002/alz.12372
Alzheimer's & Dementia, Vol. 18 Núm. 1 (january 2022) , p. 159-177
|
|
|
6.
|
|
13 p, 1.8 MB |
Replication study of plasma proteins relating to Alzheimer's pathology
/
Shi, Liu (University of Oxford. Department of Psychiatry) ;
Winchester, Laura M. (University of Oxford. Department of Psychiatry) ;
Westwood, Sarah (University of Oxford. Department of Psychiatry) ;
Baird, Alison L (University of Oxford. Department of Psychiatry) ;
Anand, Sneha N (University of Oxford. Department of Psychiatry) ;
Buckley, Noel J. (University of Oxford. Department of Psychiatry) ;
Hye, Abdul (Maurice Wohl Clinical Neuroscience. Institute of Psychiatry. Psychology and Neuroscience. Kings College London) ;
Ashton, Nicholas J. (University of Gothenburg) ;
Bos, Isabelle (Alzheimer Center. VU University Medical Center) ;
Vos, Stephanie J.B. (Maastricht University. School for Mental Health and Neuroscience) ;
Kate, Mara Ten (Amsterdam UMC. University Medical Center) ;
Scheltens, Philip (Amsterdam UMC. University Medical Center) ;
Teunissen, Charlotte E. (Amsterdam University Medical Centers (AUMC)) ;
Vandenberghe, Rik (University Hospitals Leuven (Bèlgica)) ;
Gabel, Silvy (KU Leuven. Laboratory for Cognitive Neurology) ;
Meersmans, Karen (KU Leuven. Laboratory for Cognitive Neurology) ;
Engelborghs, Sebastiaan (Department of Neurology. UZ Brussel and Center for Neurociences (C4N). Vrije Universiteit Brussel) ;
De Roeck, Ellen E (Department of Neurology and Memory Clinic. Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken) ;
Sleegers, Kristel (University of Antwerp. Institute Born-Bunge) ;
Frisoni, Giovanni B. (IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli) ;
Blin, Olivier (AIX marseille university. INS. Ap-hm) ;
Richardson, Jill C. (Neurosciences Therapeutic Area. GlaxoSmithKline R&D) ;
Bordet, Régis (Inserm. University of Lille. CHU Lille) ;
Molinuevo, José Luis (Barcelonaβeta Brain Research Center (BBRC)) ;
Rami Gonzalez, Lorena (Barcelonaβeta Brain Research Center (BBRC)) ;
Wallin, Anders (Institute of Neuroscience and Physiology. Sahlgrenska Academy at University of Gothenburg) ;
Kettunen, Petronella (Institute of Neuroscience and Physiology. Sahlgrenska Academy at University of Gothenburg) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Verhey, Frans (Maastricht University. School for Mental Health and Neuroscience) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Sala, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Popp, Julius (Geriatric Psychiatry. Department of Mental Health and Psychiatry. Geneva University Hospitals) ;
Peyratout, Gwendoline (Lausanne University Hospital) ;
Martinez-Lage, Pablo (CITA-Alzheimer Foundation) ;
Tainta, Mikel (CITA-Alzheimer Foundation) ;
Johannsen, Peter (Danish Dementia Research Centre. Rigshospitalet. Copenhagen University Hospital) ;
Freund-Levi, Yvonne (Karolinska Institutet Center for Alzheimer Research. Division of Clinical Geriatrics. School of Medical Sciences Örebro University and Department of Neurobiology. Caring Sciences and Society (NVS)) ;
Frölich, Lutz (Department of Geriatric Psychiatry. Zentralinstitut für Seelische Gesundheit. University of Heidelberg) ;
Dobricic, Valerija (Lübeck Interdisciplinary Platform for Genome Analytics. Institutes of Neurogenetics and Cardiogenetics. University of Lübeck) ;
Legido-Quigley, Cristina (The Systems Medicine Group. Steno Diabetes Center) ;
Barkhof, Frederik (UCL Institutes of Neurology and Healthcare Engineering) ;
Andreasson, Ulf (Clinical Sahlgrenska University Hospital) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia)) ;
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit)) ;
Streffer, Johannes (UCB. Braine-l'Alleud. Belgium. formerly Janssen R&D. LLC Beerse) ;
Lill, Christina M. (Ageing Epidemiology Research Unit. School of Public Health. Imperial College) ;
Bertram, Lars (Department of Psychology. University of Oslo) ;
Visser, Pieter Jelle (Alzheimer Center. VU University Medical Center) ;
Kolb, Hartmuth C. (Janssen R&D) ;
Narayan, Vaibhav A. (Janssen R&D) ;
Lovestone, Simon (Janssen R&D) ;
Nevado-Holgado, Alejo (Department of Psychiatry. University of Oxford)
Introduction: This study sought to discover and replicate plasma proteomic biomarkers relating to Alzheimer's disease (AD) including both the "ATN" (amyloid/tau/neurodegeneration) diagnostic framework and clinical diagnosis. [...]
2021 - 10.1002/alz.12322
Alzheimer's & Dementia, Vol. 17 Núm. 9 (september 2021) , p. 1452-1464
|
|
|
7.
|
|
13 p, 2.5 MB |
TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels
/
Hong, Shengjun (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA). University of Lübeck) ;
Dobricic, Valerija (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA). University of Lübeck) ;
Ohlei, Olena (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA). University of Lübeck) ;
Bos, Isabelle (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Vrije Universiteit Amsterdam) ;
Vos, Stephanie J.B. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Vrije Universiteit Amsterdam) ;
Prokopenko, Dimitry (Massachusetts General Hospital (Boston)) ;
Tijms, Betty M. (Vrije Universiteit Amsterdam) ;
Andreasson, Ulf (Sahlgrenska University Hospital (Suècia)) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia)) ;
Vandenberghe, Rik (University Hospitals Leuven (Bèlgica)) ;
Gabel, Silvy (KU Leuven. Department of Neurosciences) ;
Scheltens, Philip (Vrije Universiteit Amsterdam) ;
Teunissen, Charlotte E. (Amsterdam University Medical Centers (AUMC)) ;
Engelborghs, Sebastiaan (Vrije Universiteit Brussel) ;
Frisoni, Giovanni B. (IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli) ;
Blin, Olivier (AIX Marseille University. INS. Ap-hm) ;
Richardson, Jill C. (Neurosciences Therapeutic Area. GlaxoSmithKline R&D) ;
Bordet, Régis (Inserm. CHU Lille. University of Lille) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Popp, Julius (Lausanne University Hospital) ;
Clark, Christopher (University Hospital of Psychiatry Zurich) ;
Peyratout, Gwendoline (University Hospital of Lausanne. Department of Psychiatry) ;
Martinez-Lage, Pablo (Department of Neurology. Center for Research and Advanced Therapies. CITA-Alzheimer Foundation) ;
Tainta, Mikel (Department of Neurology. Center for Research and Advanced Therapies. CITA-Alzheimer Foundation) ;
Dobson, Richard J.B. (University College London. Hospitals Biomedical Research Centre) ;
Legido-Quigley, Cristina (King's College London) ;
Sleegers, Kristel (University of Antwerp. Institute Born-Bunge) ;
Van Broeckhoven, Christine (University of Antwerp) ;
Tanzi, Rudolph E. (Genetics and Aging Unit and McCance Center for Brain Health. Department of Neurology. Massachusetts General Hospital) ;
ten Kate, Mara (Amsterdam UMC. University Medical Center) ;
Wittig, Michael (Christian-Albrechts-University of Kiel. Institute of Clinical Molecular Biology) ;
Franke, Andre (Christian-Albrechts-University of Kiel. Institute of Clinical Molecular Biology) ;
Lill, Christina M. (Imperial College. School of Public Health) ;
Barkhof, Frederik (University College London. Institutes of Neurology and Healthcare Engineering) ;
Lovestone, Simon (University of Oxford. Department of Psychiatry) ;
Streffer, Johannes (Translational Medicine Neuroscience. UCB Biopharma SPRL. Braine l'Alleud) ;
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit). UK Dementia Research Institute) ;
Visser, Pieter J. (Karolinska Instutet. Department of Neurobiology) ;
Bertram, Lars (University of Oslo. Department of Psychology)
Introduction: Neurofilament light (NfL), chitinase-3-like protein 1 (YKL-40), and neurogranin (Ng) are biomarkers for Alzheimer's disease (AD) to monitor axonal damage, astroglial activation, and synaptic degeneration, respectively. [...]
2021 - 10.1002/alz.12330
Alzheimer's & Dementia, Vol. 17 Núm. 10 (october 2021) , p. 1628-1640
|
|
|
8.
|
|
16 p, 2.1 MB |
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease
/
Visser, Pieter Jelle (Karolinska Institutet (Estocolm, Suècia)) ;
Reus, Lianne M. (Vrije Universiteit Amsterdam) ;
Gobom, Johan (Sahlgrenska Academy at the University of Gothenburg) ;
Jansen, Iris E (VU University) ;
Dicks, Ellen (Vrije Universiteit Amsterdam) ;
van der Lee, Sven J. (Vrije Universiteit Amsterdam) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Verhey, Frans R. J. (Maastricht University) ;
Popp, Julius (University Hospital Zurich (Suïssa)) ;
Martinez-Lage, Pablo (Fundación CITA-Alzhéimer Fundazioa) ;
Vandenberghe, Rik (KU Leuven) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Molinuevo, José Luis (Hospital Clínic i Provincial de Barcelona) ;
Engelborghs, Sebastiaan (Vrije Universiteit Brussel) ;
Freund-Levi, Yvonne (Örebro University) ;
Froelich, Lutz (University of Heidelberg) ;
Sleegers, Kristel (University of Antwerp) ;
Dobricic, Valerija (University of Lübeck) ;
Lovestone, Simon (High Wycombe, UK) ;
Streffer, Johannes (AC Immune SA) ;
Vos, Stephanie J. B. (Maastricht University) ;
Bos, Isabelle (Maastricht University) ;
Smit, August B. (Vrije Universiteit Amsterdam) ;
Blennow, Kaj (Sahlgrenska Academy at the University of Gothenburg) ;
Scheltens, Philip (Vrije Universiteit Amsterdam) ;
Teunissen, Charlotte E. (Amsterdam University Medical Centers (AUMC)) ;
Bertram, Lars (University of Oslo) ;
Zetterberg, Henrik (Dementia Research Institute at UCL) ;
Tijms, Betty M. (Vrije Universiteit Amsterdam) ;
Universitat Autònoma de Barcelona
Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. [...]
2022 - 10.1186/s13024-022-00521-3
Molecular neurodegeneration, Vol. 17 (march 2022)
|
|
|
9.
|
|
10 p, 1.5 MB |
VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome
/
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Carmona Iragui, María (Institut d'Investigació Biomèdica Sant Pau) ;
Videla Toro, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Fernández, Susana (Institut d'Investigació Biomèdica Sant Pau) ;
Benejam, Bessy (Institut d'Investigació Biomèdica Sant Pau) ;
Pegueroles, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Barroeta, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Altuna-Azkargorta, Miren (Institut d'Investigació Biomèdica Sant Pau) ;
Valldeneu, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Xiao, Mei-Fang (Johns Hopkins University School of Medicine. Solomon H. Snyder Department of Neuroscience) ;
Xu, Desheng (Johns Hopkins University School of Medicine. Solomon H. Snyder Department of Neuroscience) ;
Núñez-Llaves, Raúl (Institut d'Investigació Biomèdica Sant Pau) ;
Querol-Vilaseca, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Sirisi Dolcet, Sonia (Institut d'Investigació Biomèdica Sant Pau) ;
Bejanin, Alexandre (Institut d'Investigació Biomèdica Sant Pau) ;
Iulita, M. Florencia (Institut d'Investigació Biomèdica Sant Pau) ;
Clarimón, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ;
Worley, Paul (Johns Hopkins University School of Medicine. Department of Neurology) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ;
Belbin, Olivia (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
There is an urgent need for objective markers of Alzheimer's disease (AD)-related cognitive impairment in people with Down syndrome (DS) to improve diagnosis, monitor disease progression, and assess response to disease-modifying therapies. [...]
2021 - 10.1186/s13195-021-00861-0
Alzheimer's research & therapy, Vol. 13 (june 2021)
|
|
|
10.
|
|
11 p, 788.5 KB |
Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer's disease
/
Siedlecki-Wullich, Dolores (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Català-Solsona, Judit (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Fábregas Ordóñez, Cristina (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Hernández, Isabel (Institut Català de Neurociènces Aplicades) ;
Clarimón, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Boada, Mercè (Institut Català de Neurociènces Aplicades) ;
Saura Antolín, Carlos (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Rodríguez Álvarez, José (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Miñano Molina, Alfredo Jesús (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Several evidences suggest that failure of synaptic function occurs at preclinical stages of Alzheimer's disease (AD) preceding neuronal loss and the classical AD pathological hallmarks. Nowadays, there is an urgent need to identify reliable biomarkers that could be obtained with non-invasive methods to improve AD diagnosis at early stages. [...]
2019 - 10.1186/s13195-019-0501-4
Alzheimer's research & therapy, Vol. 11 (may 2019)
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
